Clinical Trial Update: Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating chidamide in combination with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Chidamide (chidamide)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Hormone Receptor-positive Advanced Breast Cancer | Phase 2 | Status: UNKNOWN